Clinical Report: Serum Urate Goals Tied to Lower CV Risk
Overview
Achieving guideline-recommended serum urate targets is linked to a lower risk of major adverse cardiovascular events in patients with gout. A study involving over 109,000 patients demonstrated that those reaching urate levels below 6 mg/dL had a significant reduction in cardiovascular events over five years.
Background
Gout is associated with hyperuricaemia, which is recognized as an independent risk factor for cardiovascular disease. The management of serum urate levels is crucial, as achieving target levels can potentially mitigate cardiovascular risks. This study adds to the body of evidence supporting the importance of urate-lowering therapy in reducing cardiovascular events among patients with gout.
Data Highlights
| Outcome | Hazard Ratio | Absolute Survival Difference |
|---|---|---|
| Major Adverse Cardiovascular Events (Urate < 6 mg/dL) | 0.91 | ~1% |
| Major Adverse Cardiovascular Events (Urate < 5 mg/dL) | 0.77 | ~3% |
Key Findings
- 27% of patients achieved serum urate levels below 6 mg/dL within 12 months.
- 80% of those who reached the target did so within 6 months.
- Patients achieving serum urate targets had lower risks of myocardial infarction and stroke.
- The association was strongest among patients at high or very high baseline cardiovascular risk.
- Patients in the treat-to-target group experienced fewer gout flares.
Clinical Implications
Clinicians should prioritize achieving serum urate targets in patients with gout to potentially lower cardiovascular risks. Regular monitoring and adherence to urate-lowering therapy are essential components of effective management.
Conclusion
The findings underscore the importance of serum urate management in patients with gout, suggesting that achieving target levels may contribute to improved cardiovascular outcomes.
References
- JAMA Internal Medicine, 2023 -- Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout
- Conexiant, 2023 -- Do Urate Targets Influence CV Risk?
- NICE, 2023 -- Recommendations | Gout: diagnosis and management
- European Journal of Preventive Cardiology — Revisiting the Urine Albumin-Creatinine Ratio: A Timeless Indicator in Modern Cardiovascular Risk Assessment
- BMC Endocrine Disorders — The association between the triglyceride-glucose index and serum uric acid: a systematic review and meta-analysis
- Clinical Research in Cardiology — Incorporating Uric Acid into Metabolic Syndrome Criteria: Implications for Mortality Risk Assessment
- Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities - American College of Cardiology
- Revisiting the Urine Albumin-Creatinine Ratio: A Timeless Indicator in Modern Cardiovascular Risk Assessment
- Recommendations | Gout: diagnosis and management | Guidance | NICE
- Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout | Rheumatology | JAMA Internal Medicine | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
